Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting
Marko Lukic, MD PhD FEBO FASRS
On Demand Cases, Courses, and Papers
2019
Precision Subretinal Delivery for Cell and Gene Therapy
Allen C Ho, MD FASRS
Updates from the Field
2019
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Updates from the Field
2018

Category: AMD-Neovascular

See more